Trending...
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Boston: Notice of Finding of No Significant Impact and Notice of Intent to Request Release of Funds - West End Library: November 12, 2026
- City of Boston Upgrades BOS:311 App to Streamline Services for Residents
CINCINNATI, Ohio, Sept. 22, 2023 ~ Asha Therapeutics, a biopharmaceutical company that is revolutionizing the traditional multi-year drug discovery process, has been selected as a BLUE KNIGHT™ company. This joint initiative between Johnson & Johnson Innovation - JLABS and the Biomedical Advanced Research and Development Authority (BARDA) is dedicated to the acceleration of transformative technology and science that will enable a swift and targeted response to evolving threats to public health and safety.
The selection of Asha Therapeutics recognizes the potential of its proprietary PRISM™ molecular design technology platform and innovative science to transform traditional drug development. In contrast to current AI-driven systems of drug discovery that screen millions of existing compounds, the PRISMTM Platform builds custom de novo compounds for specific disease targets. PRISMTM can produce clinic-ready drugs within months, compared with traditional drug discovery that takes years due to time intensive screening and chemical optimization.
More on Boston Chron
Dr. Craig Blackstone M.D., Ph.D., a member of Asha's Board of Directors and Chair of Asha Therapeutics' Scientific Advisory Board, commented on the selection: "The selection of Asha Therapeutics as a BLUE KNIGHT™ awardee highlights the power of its proprietary PRISM™ platform to dramatically accelerate drug development for previously intractable targets, largely considered undruggable. PRISM™'s demonstrated ability to successfully drug almost any target of interest is what has impressed me the most." He went on to say that Asha has proven ability to build a portfolio of assets with disease indications including ALS, Parkinson's Disease, ME/CFS and Long Covid, and Colorectal Cancer in a matter of months, demonstrating compelling efficacy and safety in animal models.
Dr. Bradlee Heckmann, Asha's Scientific Co-Founder and Chief Scientific Officer also commented on the selection: "Asha is honored to be selected as a BLUE KNIGHTTM company...Asa has successfully used PRISMTM to rapidly design development candidates that have the extraordinary promise of becoming curative therapies that will transform patient outcomes." He went on to say they are excited to leverage the capabilities of Asha's PRISMTM technology in order to enable a rapid response to risks to public health and safety in partnership with Johnson & Johnson Innovation - JLABS and BARDA.
More on Boston Chron
Asha Therapeutics has been selected as a BLUE KNIGHTTM company in recognition for its potential in transforming traditional drug development through its proprietary PRISM™ molecular design technology platform. This joint initiative between Johnson & Johnson Innovation - JLABS and BARDA is dedicated towards accelerating transformative technology for public health safety risks. With this selection comes great promise for patients suffering from devastating illnesses who may benefit from curative therapies designed by Asha's platform in the near future.
The selection of Asha Therapeutics recognizes the potential of its proprietary PRISM™ molecular design technology platform and innovative science to transform traditional drug development. In contrast to current AI-driven systems of drug discovery that screen millions of existing compounds, the PRISMTM Platform builds custom de novo compounds for specific disease targets. PRISMTM can produce clinic-ready drugs within months, compared with traditional drug discovery that takes years due to time intensive screening and chemical optimization.
More on Boston Chron
- Not a Black Box Launches TalentOS, the First Talent Harness Operating System
- A Diwali Celebration with Heritage at South Brunswick Residents & American Properties
- Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
- What Boston Story Belongs on a Historic Marker?
- Keeping Fort Point's Famous Boston Wharf Co. Sign Glowing
Dr. Craig Blackstone M.D., Ph.D., a member of Asha's Board of Directors and Chair of Asha Therapeutics' Scientific Advisory Board, commented on the selection: "The selection of Asha Therapeutics as a BLUE KNIGHT™ awardee highlights the power of its proprietary PRISM™ platform to dramatically accelerate drug development for previously intractable targets, largely considered undruggable. PRISM™'s demonstrated ability to successfully drug almost any target of interest is what has impressed me the most." He went on to say that Asha has proven ability to build a portfolio of assets with disease indications including ALS, Parkinson's Disease, ME/CFS and Long Covid, and Colorectal Cancer in a matter of months, demonstrating compelling efficacy and safety in animal models.
Dr. Bradlee Heckmann, Asha's Scientific Co-Founder and Chief Scientific Officer also commented on the selection: "Asha is honored to be selected as a BLUE KNIGHTTM company...Asa has successfully used PRISMTM to rapidly design development candidates that have the extraordinary promise of becoming curative therapies that will transform patient outcomes." He went on to say they are excited to leverage the capabilities of Asha's PRISMTM technology in order to enable a rapid response to risks to public health and safety in partnership with Johnson & Johnson Innovation - JLABS and BARDA.
More on Boston Chron
- Boston: CPA's Historic Preservation Grants Take the Spotlight at City Hall
- Boston: Charlestown Neighbors Weigh In on the Future of Monument Square Landmark District
- Find the Good: A Citywide Scavenger Hunt Follows Boston's Historic Markers
- Holiday Magic Returns to Downtown Downers Grove November 27-29
- What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
Asha Therapeutics has been selected as a BLUE KNIGHTTM company in recognition for its potential in transforming traditional drug development through its proprietary PRISM™ molecular design technology platform. This joint initiative between Johnson & Johnson Innovation - JLABS and BARDA is dedicated towards accelerating transformative technology for public health safety risks. With this selection comes great promise for patients suffering from devastating illnesses who may benefit from curative therapies designed by Asha's platform in the near future.
Filed Under: Business
0 Comments
Latest on Boston Chron
- City of Boston Opens Public Nominations Period for New Round of Historic Markers
- Boston: Planning Advances Amendments to Linkage and Inclusionary Zoning
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Boston: National Survivors of Homicide Victims Awareness Month
- Boston: Transgender Day of Remembrance
- Boston: World Day of Remembrance for Road Traffic Victims
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
- Security Planning Tips For Your Holiday Event From Access Patrol Services
- Boston: Mayor Michelle Wu Announces Dates for the 30th Annual Enchanted Trolley Tour
- Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
- Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
- Kitchen Table Economics: An Invitation to Think Differently
- City of Boston Upgrades BOS:311 App to Streamline Services for Residents
- Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
- CB Stuffer Announces Private Sale to Secure Future of Brand Growth
- Boston: Notice of Finding of No Significant Impact and Notice of Intent to Request Release of Funds - West End Library: November 12, 2026
- Chippewa Valley Technical College selects Libman Education training materials